Phase I study of artificial tumor-antigens (GPC3/AFP/MAGE1) pulsed dendritic cell vaccination for patients with hepatocellular carcinoma

Trial Profile

Phase I study of artificial tumor-antigens (GPC3/AFP/MAGE1) pulsed dendritic cell vaccination for patients with hepatocellular carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Tella
  • Most Recent Events

    • 26 Sep 2016 Status changed from recruiting to completed.
    • 24 Mar 2014 Planned End Date 1 Jun 2014 as reported by University Hospital Medical Information Network - Japan.
    • 06 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top